Australia's lifesaving drug scheme review could require new evidence of real-life benefits
This article was originally published in Scrip
Executive Summary
Companies with drugs subsidized through the Australian Life Saving Drugs Programme (LSDP) may in future have to provide updated evidence of their products' real-life benefits or accept a price cut or delisting from the scheme, if proposals put forward in a government consultation document are taken forward.